Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [1985]

Belamaf monotherapy induced rapid responses without unexpected toxicity in...

Dr Efstathios Kastritis - National and Kapodistrian University of Athens...

$Belamaf monotherapy induced rapid responses without unexpected toxicity in relapsed or refractory light chain amyloidosis ( Dr Efstathios Kastritis - National and Kapodistrian University of Athens, Athens, Greece )$

Triplets for newly diagnosed unfit AML patients could be feasible with...

Dr Juan Miguel Bergua Burgues - Hospital San Pedro de Alcántara, Cáceres, Spain

Triplets for newly diagnosed unfit AML patients could be feasible with substantial venetoclax reduction ( Dr Juan Miguel Bergua Burgues - Hospital San Pedro de Alcántara, Cáceres, Spain )

Primary mediastinal B-cell lymphoma: Radiotherapy superfluous post...

Prof Emanuele Zucca - Oncology Institute of Southern Switzerland, Bellinzona...

Primary mediastinal B-cell lymphoma: Radiotherapy superfluous post-chemoimmunotherapy ( Prof Emanuele Zucca - Oncology Institute of Southern Switzerland, Bellinzona, Switzerland )

Axi-cel improves survival in early r/r large B-cell lymphoma

Dr Jason Westin - The University of Texas MD Anderson Cancer Center, Houston...

Axi-cel improves survival in early r/r large B-cell lymphoma ( Dr Jason Westin - The University of Texas MD Anderson Cancer Center, Houston, USA )

Teclistamab for RRMM: Long term follow up data from MajesTEC-1

Prof Niels Van de Donk - Amsterdam University Medical Center, Amsterdam...

Teclistamab for RRMM: Long term follow up data from MajesTEC-1 ( Prof Niels Van de Donk - Amsterdam University Medical Center, Amsterdam, Netherlands )

Ciltacabtagene autoleucel greatly reduces risk of disease progression in...

Dr Binod Dhakal - Medical College of Wisconsin, Milwaukee, USA

$Ciltacabtagene autoleucel greatly reduces risk of disease progression in lenalidomide-refractory MM ( Dr Binod Dhakal - Medical College of Wisconsin, Milwaukee, USA )$

Nivolumab-AVD reduces the risk of disease progression compared to brentuximab...

Dr Alex Herrera - City of Hope Comprehensive Cancer Center, Duarte, USA

Nivolumab-AVD reduces the risk of disease progression compared to brentuximab vedotin-AVD in advanced Hodgkin lymphoma ( Dr Alex Herrera - City of Hope Comprehensive Cancer Center, Duarte, USA )

PHE885 CAR-T cell therapy shows high response rates for r/r multiple myeloma in...

Prof Adam Sperling - Dana-Farber Cancer Institute, Boston, USA

PHE885 CAR-T cell therapy shows high response rates for r/r multiple myeloma in phase 1 ( Prof Adam Sperling - Dana-Farber Cancer Institute, Boston, USA )

Teclistamab plus talquetamab targeting BCMA and GPRC5D shows promise in RRMM

Dr Yael Cohen - Tel-Aviv Sourasky Medical Center, Tel Aviv, Israel

Teclistamab plus talquetamab targeting BCMA and GPRC5D shows promise in RRMM ( Dr Yael Cohen - Tel-Aviv Sourasky Medical Center, Tel Aviv, Israel )

Talquetamab plus daratumumab for RRMM: TRIMM-2 update

Prof Bhagirathbhai Dholaria - Vanderbilt University Medical Center, Nashville...

Talquetamab plus daratumumab for RRMM: TRIMM-2 update ( Prof Bhagirathbhai Dholaria - Vanderbilt University Medical Center, Nashville, USA )

Tackling low-volumes of clinical trials in Africa

Prof Ifeoma Okoye - University of Nigeria, Nsukka, Nigeria

Tackling low-volumes of clinical trials in Africa ( Prof Ifeoma Okoye - University of Nigeria, Nsukka, Nigeria )

The HypoAfrica study and AC3T research partnerships at NLCC

Dr Adedayo Joseph - NSIA-LUTH Cancer Center, Lagos, Nigeria

The HypoAfrica study and AC3T research partnerships at NLCC ( Dr Adedayo Joseph - NSIA-LUTH Cancer Center, Lagos, Nigeria )

More from ecancer